92 research outputs found
Employment and Disability Policy: the role of the psychologist
Persons with minor or major disabilities represent a significant portion of the U.S. working-age population. Based on the 1993 Survey of Income and Program Participation (SIPP), approximately 30 million (19%) men and women 18 to 64 years of age report some type of physical or mental limitation. For approximately 55% of these individuals (about 10% of those 18 to 64), the limitations are severe
Recommended from our members
Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.
IntroductionMucopolysaccharidosis (MPS) IVA or Morquio A syndrome is an autosomal recessive lysosomal storage disorder (LSD) caused by deficiency of the N-acetylgalactosamine-6-sulfatase (GALNS) enzyme, which impairs lysosomal degradation of keratan sulphate and chondroitin-6-sulphate. The multiple clinical manifestations of MPS IVA present numerous challenges for management and necessitate the need for individualised treatment. Although treatment guidelines are available, the methodology used to develop this guidance has come under increased scrutiny. This programme was conducted to provide evidence-based, expert-agreed recommendations to optimise management of MPS IVA.MethodsTwenty six international healthcare professionals across multiple disciplines, with expertise in managing MPS IVA, and three patient advocates formed the Steering Committee (SC) and contributed to the development of this guidance. Representatives from six Patient Advocacy Groups (PAGs) were interviewed to gain insights on patient perspectives. A modified-Delphi methodology was used to demonstrate consensus among a wider group of healthcare professionals with experience managing patients with MPS IVA and the manuscript was evaluated against the validated Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument by three independent reviewers.ResultsA total of 87 guidance statements were developed covering five domains: (1) general management principles; (2) recommended routine monitoring and assessments; (3) disease-modifying interventions (enzyme replacement therapy [ERT] and haematopoietic stem cell transplantation [HSCT]); (4) interventions to support respiratory and sleep disorders; (5) anaesthetics and surgical interventions (including spinal, limb, ophthalmic, cardio-thoracic and ear-nose-throat [ENT] surgeries). Consensus was reached on all statements after two rounds of voting. The overall guideline AGREE II assessment score obtained for the development of the guidance was 5.3/7 (where 1 represents the lowest quality and 7 represents the highest quality of guidance).ConclusionThis manuscript provides evidence- and consensus-based recommendations for the management of patients with MPS IVA and is for use by healthcare professionals that manage the holistic care of patients with the intention to improve clinical- and patient-reported outcomes and enhance patient quality of life. It is recognised that the guidance provided represents a point in time and further research is required to address current knowledge and evidence gaps
Recommended from our members
Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.
IntroductionMucopolysaccharidosis (MPS) VI or Maroteaux-Lamy syndrome (253200) is an autosomal recessive lysosomal storage disorder caused by deficiency in N-acetylgalactosamine-4-sulfatase (arylsulfatase B). The heterogeneity and progressive nature of MPS VI necessitates a multidisciplinary team approach and there is a need for robust guidance to achieve optimal management. This programme was convened to develop evidence-based, expert-agreed recommendations for the general principles of management, routine monitoring requirements and the use of medical and surgical interventions in patients with MPS VI.Methods26 international healthcare professionals from various disciplines, all with expertise in managing MPS VI, and three patient advocates formed the Steering Committee group (SC) and contributed to the development of this guidance. Members from six Patient Advocacy Groups (PAGs) acted as advisors and attended interviews to ensure representation of the patient perspective. A modified-Delphi methodology was used to demonstrate consensus among a wider group of healthcare professionals with expertise and experience managing patients with MPS VI and the manuscript has been evaluated against the validated Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument by three independent reviewers.ResultsA total of 93 guidance statements were developed covering five domains: (1) general management principles; (2) recommended routine monitoring and assessments; (3) enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT); (4) interventions to support respiratory and sleep disorders; (5) anaesthetics and surgical interventions. Consensus was reached on all statements after two rounds of voting. The greatest challenges faced by patients as relayed by consultation with PAGs were deficits in endurance, dexterity, hearing, vision and respiratory function. The overall guideline AGREE II assessment score obtained for the development of the guidance was 5.3/7 (where 1 represents the lowest quality and 7 represents the highest quality of guidance).ConclusionThis manuscript provides evidence- and consensus-based recommendations for the management of patients with MPS VI and is for use by healthcare professionals that manage the holistic care of patients with the intention to improve clinical- and patient-reported outcomes and enhance patient quality of life. It is recognised that the guidance provided represents a point in time and further research is required to address current knowledge and evidence gaps
Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management.
Mucopolysaccharidosis IVA (MPS IVA), also known as Morquio-Brailsford or Morquio A syndrome, is a lysosomal storage disorder caused by a deficiency of the enzyme N-acetyl-galactosamine-6-sulphate sulphatase (GALNS). MPS IVA is multisystemic but manifests primarily as a progressive skeletal dysplasia. Spinal involvement is a major cause of morbidity and mortality in MPS IVA. Early diagnosis and timely treatment of problems involving the spine are critical in preventing or arresting neurological deterioration and loss of function. This review details the spinal manifestations of MPS IVA and describes the tools used to diagnose and monitor spinal involvement. The relative utility of radiography, computed tomography (CT) and magnetic resonance imaging (MRI) for the evaluation of cervical spine instability, stenosis, and cord compression is discussed. Surgical interventions, anaesthetic considerations, and the use of neurophysiological monitoring during procedures performed under general anaesthesia are reviewed. Recommendations for regular radiological imaging and neurologic assessments are presented, and the need for a more standardized approach for evaluating and managing spinal involvement in MPS IVA is addressed
Axonal response of mitochondria to demyelination and complex IV activity within demyelinated axons in experimental models of multiple sclerosis
AIMS: Axonal injury in multiple sclerosis (MS) and experimental models is most frequently detected in acutely demyelinating lesions. We recently reported a compensatory neuronal response, where mitochondria move to the acutely demyelinated axon and increase the mitochondrial content following lysolecithin-induced demyelination. We termed this homeostatic phenomenon, which is also evident in MS, the axonal response of mitochondria to demyelination (ARMD). The aim of this study is to determine whether ARMD is consistently evident in experimental demyelination and how its perturbation relates to axonal injury.METHODS: In the present study, we assessed axonal mitochondrial content as well as axonal mitochondrial respiratory chain complex IV activity (cytochrome c oxidase or COX) of axons and related these to axonal injury in nine different experimental disease models. We used immunofluorescent histochemistry as well as sequential COX histochemistry followed by immunofluorescent labelling of mitochondria and axons.RESULTS: We found ARMD a consistent and robust phenomenon in all experimental disease models. The increase in mitochondrial content within demyelinated axons, however, was not always accompanied by a proportionate increase in complex IV activity, particularly in highly inflammatory models such as experimental autoimmune encephalomyelitis (EAE). Axonal complex IV activity inversely correlated with the extent of axonal injury in experimental disease models.CONCLUSIONS: Our findings indicate that ARMD is a consistent and prominent feature and emphasise the importance of complex IV activity in the context of ARMD, especially in autoimmune inflammatory demyelination, paving the way for the development of novel neuroprotective therapies.</p
SN 2021hpr and its two siblings in the Cepheid calibrator galaxy NGC 3147: A hierarchical BayeSN analysis of a Type Ia supernova trio, and a Hubble constant constraint
To improve Type Ia supernova (SN Ia) standardisability, the consistency of
distance estimates to siblings -- SNe in the same host galaxy -- should be
investigated. We present Young Supernova Experiment Pan-STARRS-1
photometry of SN 2021hpr, the third spectroscopically confirmed SN Ia in the
high-stellar-mass Cepheid-calibrator galaxy NGC 3147. We analyse NGC 3147's
trio of SN Ia siblings: SNe 1997bq, 2008fv and 2021hpr, using a new version of
the BayeSN model of SN Ia spectral-energy distributions, retrained
simultaneously using optical-NIR (0.35--1.8 m) data. The
distance estimates to each sibling are consistent, with a sample standard
deviation 0.01 mag, much smaller than the total intrinsic scatter in
the training sample: mag. Fitting normal SN Ia siblings
in three additional galaxies, we estimate a 90% probability that the
siblings' intrinsic scatter is smaller than . We build a new
hierarchical model that fits light curves of siblings in a single galaxy
simultaneously; this yields more precise estimates of the common distance and
the dust parameters. Fitting the trio for a common dust law shape yields
. Our work motivates future hierarchical modelling of more
siblings, to tightly constrain their intrinsic scatter, and better understand
SN-host correlations. Finally, we estimate the Hubble constant, using a Cepheid
distance to NGC 3147, the siblings trio, and 109 Hubble flow () SNe Ia; marginalising over the siblings' and population's
intrinsic scatters, and the peculiar velocity dispersion, yields
.Comment: Submitted to MNRAS; 30 pages, 22 figure
Enhanced axonal response of mitochondria to demyelination offers neuroprotection:implications for multiple sclerosis
Axonal loss is the key pathological substrate of neurological disability in demyelinating disorders, including multiple sclerosis (MS). However, the consequences of demyelination on neuronal and axonal biology are poorly understood. The abundance of mitochondria in demyelinated axons in MS raises the possibility that increased mitochondrial content serves as a compensatory response to demyelination. Here, we show that upon demyelination mitochondria move from the neuronal cell body to the demyelinated axon, increasing axonal mitochondrial content, which we term the axonal response of mitochondria to demyelination (ARMD). However, following demyelination axons degenerate before the homeostatic ARMD reaches its peak. Enhancement of ARMD, by targeting mitochondrial biogenesis and mitochondrial transport from the cell body to axon, protects acutely demyelinated axons from degeneration. To determine the relevance of ARMD to disease state, we examined MS autopsy tissue and found a positive correlation between mitochondrial content in demyelinated dorsal column axons and cytochromecoxidase (complex IV) deficiency in dorsal root ganglia (DRG) neuronal cell bodies. We experimentally demyelinated DRG neuron-specific complex IV deficient mice, as established disease models do not recapitulate complex IV deficiency in neurons,and found that these mice are able to demonstrate ARMD, despite the mitochondrial perturbation.Enhancement of mitochondrial dynamics in complex IV deficient neurons protects the axon upon demyelination. Consequently, increased mobilisation of mitochondria from the neuronal cell body to the axon is a novel neuroprotective strategy for the vulnerable, acutely demyelinated axon. We propose that promoting ARMD is likely to be a crucial preceding step for implementing potential regenerative strategies for demyelinating disorders.</p
Enhanced axonal response of mitochondria to demyelination offers neuroprotection:implications for multiple sclerosis
Axonal loss is the key pathological substrate of neurological disability in demyelinating disorders, including multiple sclerosis (MS). However, the consequences of demyelination on neuronal and axonal biology are poorly understood. The abundance of mitochondria in demyelinated axons in MS raises the possibility that increased mitochondrial content serves as a compensatory response to demyelination. Here, we show that upon demyelination mitochondria move from the neuronal cell body to the demyelinated axon, increasing axonal mitochondrial content, which we term the axonal response of mitochondria to demyelination (ARMD). However, following demyelination axons degenerate before the homeostatic ARMD reaches its peak. Enhancement of ARMD, by targeting mitochondrial biogenesis and mitochondrial transport from the cell body to axon, protects acutely demyelinated axons from degeneration. To determine the relevance of ARMD to disease state, we examined MS autopsy tissue and found a positive correlation between mitochondrial content in demyelinated dorsal column axons and cytochrome c oxidase (complex IV) deficiency in dorsal root ganglia (DRG) neuronal cell bodies. We experimentally demyelinated DRG neuron-specific complex IV deficient mice, as established disease models do not recapitulate complex IV deficiency in neurons, and found that these mice are able to demonstrate ARMD, despite the mitochondrial perturbation. Enhancement of mitochondrial dynamics in complex IV deficient neurons protects the axon upon demyelination. Consequently, increased mobilisation of mitochondria from the neuronal cell body to the axon is a novel neuroprotective strategy for the vulnerable, acutely demyelinated axon. We propose that promoting ARMD is likely to be a crucial preceding step for implementing potential regenerative strategies for demyelinating disorders.</p
Flight of the Bumblebee: the Early Excess Flux of Type Ia Supernova 2023bee revealed by , and Young Supernova Experiment Observations
We present high-cadence ultraviolet through near-infrared observations of the
Type Ia supernova (SN Ia) 2023bee in NGC~2708 ( Mpc), finding
excess flux in the first days after explosion relative to the expected
power-law rise from an expanding fireball. This deviation from typical behavior
for SNe Ia is particularly obvious in our 10-minute cadence light curve
and UV data. Compared to a few other normal SNe Ia with detected early
excess flux, the excess flux in SN 2023bee is redder in the UV and less
luminous. We present optical spectra of SN 2023bee, including two spectra
during the period where the flux excess is dominant. At this time, the spectra
are similar to those of other SNe Ia but with weaker Si II, C II and Ca II
absorption lines, perhaps because the excess flux creates a stronger continuum.
We compare the data to several theoretical models that have been proposed to
explain the early flux excess in SNe Ia. Interaction with either a nearby
companion star or close-in circumstellar material is expected to produce a
faster evolution than seen in the data. Radioactive material in the outer
layers of the ejecta, either from a double detonation explosion or simply an
explosion with a Ni clump near the surface, can not fully reproduce the
evolution either, likely due to the sensitivity of early UV observable to the
treatment of the outer part of ejecta in simulation. We conclude that no
current model can adequately explain the full set of observations. We find that
a relatively large fraction of nearby, bright SNe Ia with high-cadence
observations have some amount of excess flux within a few days of explosion.
Considering potential asymmetric emission, the physical cause of this excess
flux may be ubiquitous in normal SNe Ia.Comment: 21 pages, 12 figures. Accepted by the astrophysical journa
SN 2022oqm: A Multi-peaked Calcium-rich Transient from a White Dwarf Binary Progenitor System
We present the photometric and spectroscopic evolution of SN 2022oqm, a
nearby multi-peaked hydrogen- and helium-weak calcium-rich transient (CaRT). SN
2022oqm was detected 19.9 kpc from its host galaxy, the face-on spiral galaxy
NGC 5875. Extensive spectroscopic coverage reveals a hot (T >= 40,000 K)
continuum and carbon features observed ~1 day after discovery, SN Ic-like
photospheric-phase spectra, and strong forbidden calcium emission starting 38
days after discovery. SN 2022oqm has a relatively high peak luminosity (MB =
-17 mag) for CaRTs, making it an outlier in the population. We determine that
three power sources are necessary to explain SN 2022oqm's light curve, with
each power source corresponding to a distinct peak in its light curve. The
first peak of the light curve is powered by an expanding blackbody with a power
law luminosity, consistent with shock cooling by circumstellar material.
Subsequent peaks are powered by a double radioactive decay model, consistent
with two separate sources of photons diffusing through an optically thick
ejecta. From the optical light curve, we derive an ejecta mass and 56Ni mass of
~0.89 solar masses and ~0.09 solar masses, respectively. Detailed spectroscopic
modeling reveals ejecta that is dominated by intermediate-mass elements, with
signs that Fe-peak elements have been well-mixed. We discuss several physical
origins for SN 2022oqm and favor a white dwarf progenitor model. The inferred
ejecta mass points to a surprisingly massive white dwarf, challenging models of
CaRT progenitors.Comment: 33 pages, 17 figures, 5 tables, Submitted to Ap
- …